Fractional Senior FDA Leadership
FDA Regulatory
Consulting
FDA strategy should lead your development, not catch up to it
FDA strategy should lead your development, not catch up to it
Most regulatory delays trace back to decisions made before FDA was ever in the room: a protocol amendment that closes off a future label claim, a CMC change that triggers unplanned comparability, an indication a Type B meeting could have reshaped. We embed senior consultants who have lived inside FDA processes and translate evolving guidance into a strategy your scientists, your investors, and the agency can all defend, so the regulatory work leads the science instead of scrambling to keep up with it. It starts with the route itself: see the full map of regulatory pathways we take products through.
How the current FDA actually behaves, not how it behaved five years ago.
One senior practitioner carries your program across every function it touches, from the strategy memo behind your first investor pitch to the post-approval supplement that protects your franchise.
Integrated development plans, target product profiles, accelerated-pathway analysis, and independent gap reviews.
Question development, briefing books, and rehearsal for Type A through D and Advisory Committee meetings.
IND, NDA, BLA, 510(k), De Novo, PMA, and lifecycle filings, authored or fully managed.
IND-enabling study design, GLP toxicology oversight, and DMPK strategy across every modality.
Protocol review, endpoint and comparator selection, and clinical-regulatory issue resolution.
Comparability, process validation, specifications, and combination-product CMC strategy.
Regulatory outcomes are set at a handful of decision points, most of them years before the filing. This is where a senior lead changes the trajectory.
From first meeting to filed application, led by people who have signed the form.
Target product profile, pathway selection, and the questions worth a Type B meeting.
A fit-for-purpose nonclinical package that opens the IND without burning capital.
Endpoints, comparators, and a statistical plan that will not become NDA issues.
Comparability, validation, and specifications reviewers will actually accept.
IND, NDA, BLA, 510(k), and PMA dossiers pressure-tested before they dispatch.
Supplements, label expansions, and lifecycle commitments managed without surprises.
The people who lead your FDA work have done it before, through approvals, inspections, and the meetings that do not go to plan. What changes is how you engage them: as embedded leadership, or as a defined project with a defined end.
A named senior regulatory leader accountable for the strategy, present for the decisions, and priced to your stage, not a rotating pool of junior staff behind a partner's name.
A specific outcome with a clear end: a submission authored, a meeting package built, a gap analysis that tells you where the program really stands.
Embedded fractional leadership or a defined project — the model flexes to your stage, the seniority does not.
Our fractional regulatory leaders include former FDA reviewers, industry chief regulatory officers, and senior consultants with decades of submission and meeting experience across every major therapeutic area. You aren't staffed with junior consultants under a partner's name; you get the senior practitioner on every call.
Practitioners who have reviewed submissions, chaired meetings, and issued decisions from inside FDA, and who know how reviewers actually read your dossier.
The lead consultant on your engagement is the one doing the work. No bait-and-switch to junior staff after the contract is signed.
Our leaders span regulatory, clinical, nonclinical, CMC, and quality, because real-world regulatory problems rarely respect functional boundaries.
Small molecule, biologic, cell & gene, device, diagnostic, and digital health, across oncology, rare disease, neuroscience, and beyond.
An FDA program draws on every function at once. These are the services sponsors reach for most alongside senior strategy.
The scarce, decisive agency interactions, prepared so a single meeting lands the way the program needs it to.
Explore Meetings →The manufacturing story that most often holds up a late-stage filing, built to keep pace with the clinic.
Explore CMC →Breakthrough, Fast Track, and the other expedited routes, mapped to your program and requested at the right moment.
Explore Pathways →Tell us where you are in the development cycle and what you need. We'll match you with a senior regulatory lead and respond within one business day. All inquiries are strictly confidential.
